Literature DB >> 32108229

Bleeding in patients with sickle cell disease: a population-based study.

Nisha Hariharan1, Ann Brunson2, Anjlee Mahajan2, Theresa H M Keegan2, Ted Wun2,3.   

Abstract

Bleeding is a known complication of sickle cell disease (SCD) and includes hemorrhagic stroke, hematuria, and vitreous hemorrhage. However, the incidence of bleeding events in patients with SCD has not been well described. We present a retrospective, population-based study examining the cumulative incidence of bleeding in 6423 patients with SCD from 1991 to 2014. We also studied risk factors associated with bleeding and the effects of bleeding on mortality, using Cox proportional hazards regression models. We used California emergency department and hospitalization databases to identify patients with SCD with intracranial hemorrhage, gastrointestinal (GI) bleeding, hemophthalmos, gross hematuria, epistaxis, menorrhagia, and other bleeding events. The cumulative incidence of any first bleeding event at age 40 years was 21% (95% confidence interval [CI], 19.8%-22.3%), increasing with age to 41% by age 60 years (95% CI, 38.8%-43.1%). The majority of bleeding events were GI (41.6%), particularly from the upper GI tract. A higher bleeding risk was associated with increased frequency of hospitalization (hazard ratio [HR], 2.16; 95% CI, 1.93-2.42), venous thromboembolism 180 days before bleeding event (HR, 4.24; 95% CI, 2.86-6.28), osteonecrosis of the femoral head (HR, 1.25; 95% CI, 1.08-1.46), and ischemic stroke (HR, 1.65; 95% CI, 1.20-2.26). Bleeding was also associated with a twofold increased risk for death (HR, 2.09; 95% CI, 1.82-2.41) adjusted for other SCD-related complications. Our novel finding of a high incidence of bleeding in patients with SCD, particularly from the upper GI tract, suggests that patients with SCD may be predisposed to bleeding, with possible etiologies including increased use of nonsteroidal anti-inflammatory drugs, mucosal infarction from vascular occlusion by sickled red blood cells, and increased stress ulceration from frequent hospitalization.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2020        PMID: 32108229      PMCID: PMC7065478          DOI: 10.1182/bloodadvances.2019000940

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  38 in total

1.  Menstrual pattern in women with sickle cell anaemia and its association with sickling crises.

Authors:  W C Yoong; S M Tuck
Journal:  J Obstet Gynaecol       Date:  2002-07       Impact factor: 1.246

Review 2.  Prophylaxis against Upper Gastrointestinal Bleeding in Hospitalized Patients.

Authors:  Deborah Cook; Gordon Guyatt
Journal:  N Engl J Med       Date:  2018-06-28       Impact factor: 91.245

3.  Population based surveillance in sickle cell disease: methods, findings and implications from the California registry and surveillance system in hemoglobinopathies project (RuSH).

Authors:  Susan T Paulukonis; William T Harris; Thomas D Coates; Lynne Neumayr; Marsha Treadwell; Elliott Vichinsky; Lisa B Feuchtbaum
Journal:  Pediatr Blood Cancer       Date:  2014-08-30       Impact factor: 3.167

4.  Endoscopic and gastric acid studies in homozygous sickle cell disease and upper abdominal pain.

Authors:  M G Lee; C H Thirumalai; S I Terry; G R Serjeant
Journal:  Gut       Date:  1989-05       Impact factor: 23.059

5.  Increased risk of leukemia among sickle cell disease patients in California.

Authors:  Ann Brunson; Theresa H M Keegan; Heejung Bang; Anjlee Mahajan; Susan Paulukonis; Ted Wun
Journal:  Blood       Date:  2017-08-22       Impact factor: 22.113

6.  Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids.

Authors:  John J Strouse; Monica L Hulbert; Michael R DeBaun; Lori C Jordan; James F Casella
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

7.  The excess burden of stroke in hospitalized adults with sickle cell disease.

Authors:  John J Strouse; Lori C Jordan; Sophie Lanzkron; James F Casella
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

Review 8.  Intracranial aneurysms in sickle-cell anemia: clinical features and pathogenesis.

Authors:  N M Oyesiku; D L Barrow; J R Eckman; S C Tindall; A R Colohan
Journal:  J Neurosurg       Date:  1991-09       Impact factor: 5.115

9.  Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study.

Authors:  G F Longstreth
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

Review 10.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

View more
  3 in total

1.  Thromboprophylaxis Reduced Venous Thromboembolism in Sickle Cell Patients with Central Venous Access Devices: A Retrospective Cohort Study.

Authors:  Stéphanie Forté; Gonzalo De Luna; Jameel Abdulrehman; Nafanta Fadiga; Olivia Pestrin; Anne-Laure Pham Hung d'Alexandry d'Orengiani; John Chinawaeze Aneke; Henri Guillet; Dalton Budhram; Anoosha Habibi; Richard Ward; Pablo Bartolucci; Kevin H M Kuo
Journal:  J Clin Med       Date:  2022-02-23       Impact factor: 4.241

2.  The molecular basis for the prothrombotic state in sickle cell disease.

Authors:  Arun S Shet; Maria A Lizarralde-Iragorri; Rakhi P Naik
Journal:  Haematologica       Date:  2020-10-01       Impact factor: 9.941

3.  Absence of exaggerated pharmacology by recombinant ADAMTS13 in the rat and monkey.

Authors:  Paolo Rossato; Helmut Glantschnig; Peter Leidenmühler; Alexandra Kopic; Tanja Ruthsatz; Bernhard Majer; Maria Schuster; Friedrich Scheiflinger; Werner Höllriegl
Journal:  Blood Coagul Fibrinolysis       Date:  2022-01-01       Impact factor: 1.061

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.